drugset / Trial / NCT01598740

Evaluation of CLP With and Without Spironolactone in Heart Failure Patients With Chronic Kidney Disease

NCT01598740

Phase 1 Completed 18 enrolled Sorbent Therapeutics
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to determine the effects of CLP, with and without spironolactone, on serum, urine, and fecal contents in heart failure patients with chronic kidney disease.

Timeline

Start
2012-06
Primary completion
2012-09
Completion
2012-09

Drugs

EvaluationDrugModalityDoseRoute
Subject CLP Unknown Oral
Subject Spironolactone Small molecule Oral

Indications